Compare BioNTech SE - ADR (BNTX) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Philip Morris International Inc. — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Philip Morris International Inc. trades at $176.88 (market cap $274.23B). The key difference: Philip Morris International Inc. is far larger — about 12× BioNTech SE - ADR's market cap, and Philip Morris International Inc. pays a 3.34% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | PM | |
|---|---|---|
Market Cap | $22.86B | $274.23B |
Sector | Health | Consumer Staples |
52-Week High | $119.34 | $191.86 |
52-Week Low | $83.89 | $144.33 |
Enterprise Value | $6.53B | $320.73B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Philip Morris International (PM) trades at $175.95, down 3.12% on the day, amid a recent profit forecast revision. The stock shows a bullish technical signal with key support at $175 and resistance at $183. Fundamentally, the company reported strong 2025 results with $40.65B revenue and $11.35B net income, though a $500M impairment charge and cost pressures prompted a lowered 2026 outlook. Analyst sentiment remains positive with a $194 consensus price target and 68% buy ratings.
The outlook is cautiously optimistic; earnings growth and the IQOS brand strength offer upside, but regulatory risks and illicit market pressures pose challenges. The current price presents a potential entry point below the analyst target, though investors must weigh margin pressures from energy costs and currency swings noted in recent company guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
